Herceptin May Gain Market Share in US, Europe If Roche, Genentech Bid for Early Indication Flies | GenomeWeb

Recent moves by Roche and Genentech could expand the reach of Herceptin in Europe and the United States.

Genentech last week submitted a supplemental Biologics License Application to the US Food and Drug Administration to enable the drug to be used as an adjuvant to treat early-stage Her2-positive breast cancer, while Roche Pharmaceuticals in Switzerland submitted a Marketing Authorization application to the European Medicines Agency for the same indication.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: diatom genetic diversity, microfluidic droplet method for single-cell screening, and more.

Scientific publishers are looking into whether artificial intelligence can help the peer-review process, Wired reports.

Researchers are using gene editing to develop more robust livestock and crops, AFP reports.

Researchers rally near the American Association for the Advancement of Science annual meeting in Boston.